Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Neurology

Managing Your Brain Health and Epilepsy

At a Glance

Tuberous sclerosis complex can cause brain growths and epilepsy, often beginning in infancy. Regular MRI and EEG monitoring, prompt treatment of infantile spasms, seizure safety planning, and specialist care help protect brain development and manage complications.

Because Tuberous Sclerosis Complex (TSC) affects the way brain cells develop and grow, neurological care is a central part of managing the condition. In fact, up to 90% of people with TSC will develop epilepsy at some point in their lives [1]. Understanding the structural changes in the brain and the specialized treatments for seizures can help you work with your care team to protect brain health.

Structural Changes in the Brain

TSC causes three main types of non-cancerous growths or structural differences in the brain. These are typically monitored using regular MRI scans [2].

  • Cortical Tubers: These are areas of the brain’s surface (the cortex) where cells did not migrate correctly during development [3]. They are called “tubers” because they can feel firm, like a potato. A higher number of tubers is often linked to a higher risk of seizures and developmental challenges [4].
  • Subependymal Nodules (SENs): These are small, “pebble-like” growths that form along the walls of the fluid-filled spaces (ventricles) in the brain [5]. While many SENs do not grow, surveillance is necessary because some do.
  • Subependymal Giant Cell Astrocytomas (SEGAs): In a subset of cases, an SEN can grow and become a SEGA [5]. SEGA assessment depends on location, serial growth, imaging characteristics, and clinical context; a stable lesion over 1 cm is not automatically a SEGA, and a smaller growing lesion may be clinically important [6]. Because SEGAs grow near the narrow passages where brain fluid (CSF) flows, they can cause a dangerous buildup of pressure called hydrocephalus [7].

TSC-Associated Epilepsy

Seizures in TSC often begin in the first year of life [8]. There are two main types that parents and patients should watch for:

Infantile Spasms (A Medical Emergency)

These are a medical emergency requiring same-day urgent assessment. They often look like subtle “jackknife” clusters where a baby’s head drops forward and their arms or legs stiffen for a few seconds, but they can also be subtle extensions or pauses [9]. Because they can be mistaken for colic or a startle reflex, any repetitive, clustered movements must be evaluated immediately. If safe, record a video of the event to show the doctor, and do not wait for a routine visit.

Focal Seizures

These seizures start in one specific part of the brain, often near a cortical tuber. They might cause rhythmic twitching on one side of the body, staring spells, or unusual repetitive movements [1][10].

Seizure Emergencies and First Aid

Every patient with epilepsy needs a clinician-provided seizure action plan. You must call emergency services (like 911) if:

  • A seizure lasts for 5 minutes or longer.
  • Repeated seizures occur without the person waking up or recovering in between.
  • The person has difficulty breathing or changes color.
  • The person is seriously injured, or it is their first-ever seizure.

Basic First Aid: Keep the person safe from injury, time the seizure, do NOT hold them down, and do NOT put anything in their mouth. Administer rescue medications exactly as prescribed.

Specialized Treatments

The goal of treatment is to stop seizures as quickly as possible to allow the brain to develop normally.

Early EEG Screening

Current consensus guidelines recommend an age-specific approach for electroencephalogram (EEG) tests. A baseline EEG is performed upon diagnosis. In seizure-free young children, routine EEGs are typically repeated approximately every 3 months through 24 months, and every 6 months from 24 to 48 months [11]. If symptoms arise or an abnormal routine EEG warrants it, urgent or prolonged video-EEG is required [8].

Vigabatrin and Preemptive Treatment

Vigabatrin is the gold-standard treatment for infantile spasms in TSC [1]. It works by increasing levels of a calming chemical in the brain.

  • Preemptive Use: For infants with specific, highly concerning epileptiform abnormalities on their EEG, a specialist may recommend starting vigabatrin before clinical seizures begin to potentially delay or reduce epilepsy severity [8][12]. This is a complex risk-benefit decision.
  • Key Risks: Vigabatrin carries a risk of permanent visual field loss (loss of peripheral vision) [13]. It can also cause temporary changes on a brain MRI, known as VABAM (vigabatrin-associated brain abnormalities on MRI), which usually disappear once the medicine is stopped [14][15].

Managing SEGAs

If a SEGA is found, there are two main ways to treat it:

  1. mTOR Inhibitors (Everolimus): This medication targets the underlying genetic pathway, often shrinking SEGAs without the need for surgery [16][17].
  2. Surgery: If a SEGA is growing rapidly or causing immediate pressure in the brain, it may need to be surgically removed [18].

When Medications Aren’t Enough

If two or more standard anti-seizure medicines fail to control the seizures, the epilepsy is considered drug-resistant [19]. At this point, other options are considered:

  • Epilepsy Surgery: Early evaluation is critical. If a specific tuber can be identified as the source of the seizures, a surgeon may remove or disconnect that area [20].
  • Everolimus or Cannabidiol (CBD): These medications are FDA-approved as “add-on” treatments for TSC-related seizures [21][22].
  • Ketogenic Diet: A specialized high-fat, low-carbohydrate diet, managed by a medical team, has been shown to significantly reduce seizures in many children with TSC [23].

Common questions in this guide

How often should a child with TSC have EEG testing?
A baseline EEG is recommended when TSC is diagnosed. In seizure-free young children, routine EEGs are typically repeated about every 3 months through age 24 months and every 6 months from 24 to 48 months. New symptoms or an abnormal routine EEG may require urgent or prolonged video-EEG testing.
What do cortical tubers, SENs, and SEGAs mean on a TSC brain MRI?
Cortical tubers are areas where brain cells developed differently, while subependymal nodules, or SENs, form along the walls of the brain's fluid-filled spaces. Some SENs can grow into subependymal giant cell astrocytomas, or SEGAs, which may block fluid flow and cause hydrocephalus. Doctors assess their size, location, growth over time, imaging features, and clinical effects.
What do infantile spasms look like in TSC, and when should I seek help?
Infantile spasms may appear as repeated clusters of head drops, body bending, limb stiffening, brief extensions, or pauses. They can resemble colic or a startle response, so any repetitive clustered movements need same-day urgent medical assessment. If it is safe, record a video to show the medical team and do not wait for a routine appointment.
When is a seizure in someone with TSC an emergency?
Call emergency services if a seizure lasts 5 minutes or longer, seizures repeat without recovery, breathing or skin color changes, serious injury occurs, or it is the person's first seizure. Keep the person safe, time the seizure, do not restrain them or put anything in their mouth, and give prescribed rescue medicine exactly as directed.
What is vigabatrin used for in TSC?
Vigabatrin is the standard treatment for infantile spasms associated with TSC and may sometimes be started before visible seizures when an EEG shows highly concerning abnormalities. It can cause permanent loss of peripheral vision and temporary MRI changes, so treatment requires specialist monitoring and an individualized risk-benefit discussion.
How are SEGAs treated in people with TSC?
Everolimus, an mTOR-targeting medicine, can often shrink a SEGA without surgery. A rapidly growing SEGA or one causing immediate pressure on the brain may require surgical removal. The choice depends on the lesion's growth, location, imaging features, and clinical effects.
What can help when TSC seizures do not respond to standard medicines?
Epilepsy is considered drug-resistant when two or more standard anti-seizure medicines fail to control seizures. Options may include early evaluation for epilepsy surgery, add-on everolimus or cannabidiol, and a medically supervised ketogenic diet. Treatment decisions should be made with a team experienced in TSC-related epilepsy.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.What is the current size and clinical context of any subependymal nodules (SENs) or tumors (SEGAs) on my/my child's most recent MRI?
  2. 2.What is the exact age-specific schedule we should follow for EEG screenings?
  3. 3.If we use vigabatrin, how will you monitor for visual field loss, and at what point would we consider switching medications?
  4. 4.Are there any specific cortical tubers that seem to be the 'trigger' for the seizures, and would they be candidates for early epilepsy surgery evaluation?
  5. 5.Do we have an updated, written seizure rescue plan, and when should I administer emergency medication?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (23)
  1. 1

    Update on Drug Management of Refractory Epilepsy in Tuberous Sclerosis Complex.

    van der Poest Clement E, Jansen FE, Braun KPJ, Peters JM

    Paediatric drugs 2020; (22(1)):73-84 doi:10.1007/s40272-019-00376-0.

    PMID: 31912454
  2. 2

    Subependymal Giant Cell Astrocytoma Size Measurement in Tuberous Sclerosis Complex: Noncontrast vs Contrast-Enhanced 3-Dimensional T1-Weighted Magnetic Resonance Imaging (MRI).

    Hill BJ, Gadde JA, Palasis S

    Journal of child neurology 2019; (34(14)):922-927 doi:10.1177/0883073819867541.

    PMID: 31424303
  3. 3

    Unique findings of subependymal giant cell astrocytoma within cortical tubers in patients with tuberous sclerosis complex: a histopathological evaluation.

    Katz JS, Frankel H, Ma T, et al.

    Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery 2017; (33(4)):601-607 doi:10.1007/s00381-017-3335-z.

    PMID: 28074282
  4. 4

    Association of Early MRI Characteristics With Subsequent Epilepsy and Neurodevelopmental Outcomes in Children With Tuberous Sclerosis Complex.

    Hulshof HM, Kuijf HJ, Kotulska K, et al.

    Neurology 2022; (98(12)):e1216-e1225 doi:10.1212/WNL.0000000000200027.

    PMID: 35101906
  5. 5

    Erk activation as a possible mechanism of transformation of subependymal nodule into subependymal giant cell astrocytoma.

    Siedlecka M, Szlufik S, Grajkowska W, et al.

    Folia neuropathologica 2015; (53(1)):8-14 doi:10.5114/fn.2015.49969.

    PMID: 25909870
  6. 6

    Subependymal giant cell astrocytoma (SEGA): a case report and review of the literature.

    Tahiri Elousrouti L, Lamchahab M, Bougtoub N, et al.

    Journal of medical case reports 2016; (10()):35 doi:10.1186/s13256-016-0818-6.

    PMID: 26861567
  7. 7

    The coding and non-coding transcriptional landscape of subependymal giant cell astrocytomas.

    Bongaarts A, van Scheppingen J, Korotkov A, et al.

    Brain : a journal of neurology 2020; (143(1)):131-149 doi:10.1093/brain/awz370.

    PMID: 31834371
  8. 8

    Prevention of Epilepsy in Infants with Tuberous Sclerosis Complex in the EPISTOP Trial.

    Kotulska K, Kwiatkowski DJ, Curatolo P, et al.

    Annals of neurology 2021; (89(2)):304-314 doi:10.1002/ana.25956.

    PMID: 33180985
  9. 9

    Efficacy and safety of vigabatrin in patients with tuberous sclerosis complex and infantile epileptic spasm syndrome: a systematic review.

    Prezioso G, Chiarelli F, Matricardi S

    Expert review of neurotherapeutics 2023; (23(7)):661-671 doi:10.1080/14737175.2023.2216385.

    PMID: 37243682
  10. 10

    Focal Epilepsy in Children With Tuberous Sclerosis Complex: Does Vigabatrin Control Focal Seizures?

    Lin S, Liao J, Zhao X, et al.

    Journal of child neurology 2022; (37(5)):329-333 doi:10.1177/08830738211048326.

    PMID: 35321578
  11. 11

    Management of epilepsy associated with tuberous sclerosis complex: Updated clinical recommendations.

    Curatolo P, Nabbout R, Lagae L, et al.

    European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(5)):738-748 doi:10.1016/j.ejpn.2018.05.006.

    PMID: 29880258
  12. 12

    Early Treatment with Vigabatrin Does Not Decrease Focal Seizures or Improve Cognition in Tuberous Sclerosis Complex: The PREVeNT Trial.

    Bebin EM, Peters JM, Porter BE, et al.

    Annals of neurology 2023; doi:10.1002/ana.26778.

    PMID: 37638552
  13. 13

    Vigabatrin-related adverse events for the treatment of epileptic spasms: systematic review and meta-analysis.

    Biswas A, Yossofzai O, Vincent A, et al.

    Expert review of neurotherapeutics 2020; (20(12)):1315-1324 doi:10.1080/14737175.2020.1840356.

    PMID: 33078964
  14. 14

    Vigabatrin-associated brain magnetic resonance imaging abnormalities and clinical symptoms in infants with tuberous sclerosis complex.

    Stevering C, Lequin M, Szczepaniak K, et al.

    Epilepsia 2025; (66(2)):356-368 doi:10.1111/epi.18190.

    PMID: 39641935
  15. 15

    A Case of Vigabatrin Toxicity Mimicking Bilateral Thalamic Infarcts on MRI.

    Lockard TJ, Rathore G

    Cureus 2023; (15(9)):e45049 doi:10.7759/cureus.45049.

    PMID: 37829947
  16. 16

    Everolimus.

    Hasskarl J

    Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer 2018; (211()):101-123 doi:10.1007/978-3-319-91442-8_8.

    PMID: 30069763
  17. 17

    Long-Term Use of Everolimus in Patients with Tuberous Sclerosis Complex: Final Results from the EXIST-1 Study.

    Franz DN, Belousova E, Sparagana S, et al.

    PloS one 2016; (11(6)):e0158476 doi:10.1371/journal.pone.0158476.

    PMID: 27351628
  18. 18

    Acute Management of Symptomatic Subependymal Giant Cell Astrocytoma With Everolimus.

    Arroyo MS, Krueger DA, Broomall E, et al.

    Pediatric neurology 2017; (72()):81-85 doi:10.1016/j.pediatrneurol.2017.04.008.

    PMID: 28511812
  19. 19

    Overview of therapeutic options for epilepsy.

    Kuchenbuch M, Chiron C, Milh M

    Archives de pediatrie : organe officiel de la Societe francaise de pediatrie 2022; (29(5S)):5S14-5S19 doi:10.1016/S0929-693X(22)00285-8.

    PMID: 36585066
  20. 20

    The role of neurosurgery in the management of tuberous sclerosis complex-associated epilepsy: a systematic review.

    Nie JZ, Karras CL, Trybula SJ, et al.

    Neurosurgical focus 2022; (52(5)):E6 doi:10.3171/2022.2.FOCUS21789.

    PMID: 35535822
  21. 21

    Genetic pathogenesis of the epileptogenic lesions in Tuberous Sclerosis Complex: Therapeutic targeting of the mTOR pathway.

    Moavero R, Mühlebner A, Luinenburg MJ, et al.

    Epilepsy & behavior : E&B 2022; (131(Pt B)):107713 doi:10.1016/j.yebeh.2020.107713.

    PMID: 33431351
  22. 22

    Review of the treatment options for epilepsy in tuberous sclerosis complex: towards precision medicine.

    Schubert-Bast S, Strzelczyk A

    Therapeutic advances in neurological disorders 2021; (14()):17562864211031100 doi:10.1177/17562864211031100.

    PMID: 34349839
  23. 23

    Ketogenic Diet for the Management of Epilepsy Associated with Tuberous Sclerosis Complex in Children.

    Park S, Lee EJ, Eom S, et al.

    Journal of epilepsy research 2017; (7(1)):45-49 doi:10.14581/jer.17008.

    PMID: 28775955

This page explains brain monitoring, epilepsy, and treatments in tuberous sclerosis complex for educational purposes and does not replace medical advice. A neurologist or TSC care team should tailor MRI, EEG, seizure-emergency, and medication decisions to you or your child.

Get notified when new evidence is published on Tuberous sclerosis complex.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.